Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06434194 · ClinicalTrials.gov registry record · NA

Serrantor OCT Study

A NA study of Critical Limb Ischemia, sponsored by Cagent Vascular.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
2
Study locations

NCT06434194 is a NA study of Critical Limb Ischemia that is actively recruiting participants, run by Cagent Vascular. The registered enrollment target is 60 participants, below the 88-participant average among 18 other Critical Limb Ischemia trials with a reported enrollment target (32% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06434194, a NA study of Critical Limb Ischemia, is actively recruiting participants, sponsored by Cagent Vascular.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

TA prospective randomized control trial to evaluate the serration angioplasty effect in BTK arteries with varying degrees of calcified plaque.

Conditions Studied

Interventions

  • DEVICE Serranator PTA Serration Catheter
  • DRUG PTA (Standard of Care)

Study Locations (2)

New York

  • Columbia University - New York
  • Weill Cornell Medical - New York

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-10-31
Est. Completion 2025-06-01
Phase NA

Sponsor

Cagent Vascular

2 total trials

What the Registry Record Tells You About NCT06434194

The ClinicalTrials.gov registry entry for NCT06434194 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 18 other Critical Limb Ischemia trials with a reported enrollment target (32% lower). The listed sponsor is Cagent Vascular, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Critical Limb Ischemia appearing as the primary indexed condition, and to 2 interventions - of which Serranator PTA Serration Catheter is the first listed.

NCT06434194 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06434194 about?

NCT06434194 is a clinical study titled "Serrantor OCT Study". TA prospective randomized control trial to evaluate the serration angioplasty effect in BTK arteries with varying degrees of calcified plaque.

What is the current status of trial NCT06434194?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-10-31. Estimated completion is 2025-06-01.

What conditions does trial NCT06434194 study?

This clinical trial studies the following conditions: Critical Limb Ischemia.

What interventions are being tested in trial NCT06434194?

The interventions under investigation include: Serranator PTA Serration Catheter (DEVICE), PTA (Standard of Care) (DRUG).

Who is sponsoring clinical trial NCT06434194?

This trial is sponsored by Cagent Vascular, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06434194 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Critical Limb Ischemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.